Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 5, 2011, Pages 1251-1256

  Yang, Xue Qin ^a,b   Chen, Chuang ^a   Wang, Fu Bing ^a   Peng, Chun Wei ^a   Li, Yan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b University of Technology   (China)

Author keywords

CA 19 9; CA 125; CEA; China; Colorectal cancer; Recurrence free survival

Indexed keywords

EID: 84863266904     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Auf FA, El-Ebidy GK, Mosaad YM, et al (2010). Cytokeratin 20 and vascular endothelial growth factor as molecular markers in Egyptian patients with colorectal cancer. J Oncol Pharm Pract, (Epub ahead of print).
2. Baron AT, Boardman CH, Lafky JM, et al (2005). Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev, 14, 306-18.
3. Demirci U, Coskun U, Sancak B, et al (2009). Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pac J Cancer Prev, 10, 1021-24.
4. Dogan L, Karaman N, Yilmaz KB, et al (2010). Characteristics and risk factors for colorectal cancer recurrence. J BUON, 15, 61-67.
5. Duffy MJ, van Dalen A, Haglund C, et al (2007).Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer, 43, 1348-60.
6. Duffy MJ (2001). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem, 47, 624-30.
7. Ferroni P, Roselli M, Spila A, et al (2010). Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer, 116, 2913-21.
8. Holten-Andersen M, Christensen IJ, Nilbert M, et al (2004). Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. Eur J Cancer, 40, 64-72.
9. Holten-Andersen MN, Fenger C, Nielsen HJ, et al (2004). Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer, 40, 2159-64.
10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
11. Kim HJ, Yu MH, Kim H, et al (2008). Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep, 41, 685-92.
12. Locker GY, Hamilton S, Harris J, et al (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24, 5313-27.
13. Ministery of Health of the People's Republic of China (2010). Mortality rate of 10 main malignant neoplasms from 2004 to 2005. Available from: http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010/index2010.html. Accessed March, 22, 2011.
14. Miralles C, Orea M, España P, et al (2003). Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol, 10, 150-54.
15. Morita S, Nomura T, Fukushima Y, et al (2004). Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum, 47, 227-32.
16. Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, et al (2007). Serum macrophagecolony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta, 380, 208-12.
17. Papk IJ, Choi GS, Jun SH (2009). Prognostic value of serum tumor antigen ca19-9 after curative resection of colorectal cancer. Anticancer Res, 29, 4303-308.
18. Park IJ, Choi GS, Lim KH, et al (2009). Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol, 16, 3087-93.
19. Rosen DG, Wang L, Atkinson JN, et al (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 99, 267-77.
20. Sun LC, Chu KS, Cheng SC, et al (2009). Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer, 9, 288-95.
21. Tang R, Yeh CY, Wang JY, et al (2009). Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol, 16, 2516-23.
22. Yang XQ, Yan L, Chen C, et al (2009). Application of C12 multitumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepato-gastroenterology, 56, 1388-94.
23. Yang XQ, Li Y, Chen C, et al (2010). Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer. Med Oncol, (Epub ahead of print).
24. Zhang YH, Li Y, Chen C, et al (2009). Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy. Hepato-gastroenterology, 56, 285-89.